Search Results
Your search for ,aGe matches 8736 pages
Showing 4601 - 4650ASBrS 2018: Modern Therapies Minimize Recurrence After Breast-Conserving Surgery
Modern, multimodality lumpectomy treatment significantly reduces the incidence of breast cancer recurrence at the original tumor site compared to historical protocols, according to a new study presented at the American Society of Breast Surgeons (ASBrS) 19th Annual Meeting (Abstract...
ASBrS 2018: Regular Mammograms May Mean Earlier Breast Cancer Diagnosis and Less Aggressive Treatment
Women with breast cancer who underwent regular mammographic screening were diagnosed with earlier-stage disease and treated with significantly less aggressive therapies than those who delayed or never underwent screening, according to new research presented at the American Society of Breast...
Survivors of Uterine Cancer Have Increased Risk of Heart Disease Years After Treatment Has Ended
A large population-based study by Soisson et al examining the long-term cardiovascular outcomes among survivors of endometrial cancer has found that women were at higher risk for a number of cardiovascular risks, including hypertension; diseases of the arteries, arterioles, and capillaries;...
Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
Updated results of a phase I/II study of durvalumab (Imfinzi) in locally advanced or metastatic urothelial carcinoma were reported by Thomas Powles, MD, of Barts Cancer Institute, Queen Mary University of London, and colleagues in JAMA Oncology. Data from the ongoing study supported the recent...
Dispel Fears About Breast Cancer Radiotherapy With ‘Real Truth’ About Modern Techniques and Side Effects
Nearly 85% of patients surveyed 6 or more months after completing radiotherapy as part of their treatment for breast cancer reported the side effects were not as bad as they had feared or expected. Approximately 92% of the 269 patients treated with breast conservation and 81% of the 58 patients...
Spring
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Doctoring Is a Family Tradition for Medical Oncologist Virginia G. Kaklamani, MD
Virginia G. Kaklamani, MD, Professor of Hematology/Oncology at the UT Health Science Center San Antonio and leader of the center’s breast cancer program, was born and reared in Athens, Greece. “I spent my formative years in Athens, where I attended school. My father is a physician and my mom’s a...
Disparities Found in Lung Cancer Care, Survival in United States vs England
Despite steady declines in death rates in recent years, lung cancer remains the leading cause of cancer deaths in wealthy countries. In a study published by Andreano et al in the Journal of Thoracic Oncology, Yale researchers collaborated with investigators in Europe to examine lung cancer care and ...
Nivolumab in Adjuvant Treatment of Melanoma
On December 20, 2017, nivolumab (Opdivo) was granted regular approval for adjuvant treatment of patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection.1,2 Nivolumab was previously approved for the treatment of patients with unresectable or...
Combined Immune Checkpoint and VEGF Inhibition as First-Line Therapy in Advanced Clear Cell Kidney Cancer
In a dose-finding, dose-expansion phase Ib trial (JAVELIN Renal 100) reported in The Lancet Oncology, Toni K. Choueiri, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and colleagues determined the maximum tolerated dose of the immune checkpoint inhibitor avelumab (Bavencio)...
Prediction of Late Distant Recurrence in Estrogen Receptor–Positive Breast Cancer After 5 Years of Endocrine Therapy
As reported in the Journal of Clinical Oncology, Dowsett et al have developed a clinicopathologic tool for predicting risk of late distant recurrence in estrogen receptor (ER)-positive breast cancer treated with 5 years of endocrine therapy. Study Details In the study, a prognostic score for...
By 2030, Prostate and Lung Cancers Are Expected to Be the Most Common Cancer Types Among HIV-Infected Adults
While effective antiretroviral therapy, which suppresses HIV replication and improves immune function, has resulted in increased longevity for people living with HIV and reduced the risk of certain cancers, including Kaposi sarcoma and non-Hodgkin lymphoma, other cancers are expected to become more ...
FDA Expands Tisagenlecleucel Approval to Include Relapsed or Refractory Large B-Cell Lymphoma
On May 1, the U.S. Food and Drug Administration (FDA) approved tisagenlecleucel (Kymriah) suspension for intravenous infusion for the treatment of adult patients with relapsed or refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and...
MGUS and Multiple Myeloma in 9/11 Firefighters
A study by Landgren et al in JAMA Oncology has found that New York City firefighters exposed to the 9/11 World Trade Center (WTC) disaster site face an increased risk for developing monoclonal gammopathy of undetermined significance (MGUS), a myeloma precursor disease. The study was conducted...
Adverse Financial Impact of Breast Cancer for Black vs White Women
In a study reported in the Journal of Clinical Oncology, Wheeler et al found that black women experience significantly worse financial impact from breast cancer compared with white women, which may contribute to barriers to treatment compliance and worse outcomes. Study Details The...
Diagnosis-to-Treatment Interval and Outcome in Newly Diagnosed DLBCL
In a study reported in the Journal of Clinical Oncology, Maurer et al found that a shorter interval between diagnosis and treatment was associated with adverse prognostic features and that a longer interval was associated with greater event-free survival in the first-line treatment of diffuse large ...
Infection-Associated Late Mortality in Childhood Cancer Survivors Undergoing Splenectomy or Splenic Radiation
In a report from the Childhood Cancer Survivor Study published in the Journal of Clinical Oncology, Weil et al found that splenectomy and splenic radiation significantly increased the risk of infection-related late mortality among 5-year survivors of childhood cancer. Study Details The study...
Concordance of Non–Low-Risk Prostate Cancer Among Brother Pairs
In a Swedish study reported in the Journal of Clinical Oncology, Jansson et al identified an increased risk of non–low-risk prostate cancer among men with prostate cancer who had with brothers diagnosed with non–low-risk disease. Study Details The study involved 4,262 pairs of...
ESTRO 37: Positioning for Radiotherapy and Impact on Survival in Patients With Lung or Esophageal Cancers
Very small differences in the way a patient lies during radiotherapy treatment for lung or esophageal cancer can have an impact on survival, according to research presented at the European Society for Radiotherapy & Oncology (ESTRO) 37 Conference (Abstract OC-0322). These differences of only a...
ESTRO 37: Handgrip Strength Test May Be a Good Indicator of Survival in Patients With NSCLC
A simple test of handgrip strength may be a good indicator of short- and long-term survival in patients with stage I non–small cell lung cancer (NSCLC), according to new findings presented at the European Society for Radiotherapy & Oncology (ESTRO) 37 Conference (Abstract PV0041)....
Link Between Risk of Alzheimer’s Disease and Melanoma, Nonmelanoma Skin Cancers
Although literature demonstrates a decreased risk of Alzheimer's disease in individuals with various cancers—including squamous cell cancers (SCC) and basal cell cancers (BCC)—there is a paucity of literature to substantiate an association between malignant melanoma and...
Family History and Contralateral Breast Cancer Risk in Young Women
In an update from the WECARE (Women’s Environmental Cancer and Radiation Epidemiology) study reported in the Journal of Clinical Oncology, Reiner et al found that women with invasive breast cancer are at increased risk of contralateral breast cancer even in the absence of deleterious...
Morbidity in Testicular Cancer Survivors Treated With Standard Cisplatin-Based Chemotherapy
In a study reported in the Journal of Clinical Oncology, Kerns et al found that approximately 20% of testicular cancer survivors treated with cisplatin-based regimens had high cumulative burden of morbidity (CBM) scores and identified factors associated with risk for increased morbidity. Study...
Cancer Cost Planning and Accounting for Patients Under 65
A new study published by Banegas et al in JNCCN–Journal of the National Comprehensive Cancer Network has found that cancer care costs in the United States are higher for people under age 65—and that costs increase with disease stage. Despite the fact that nearly half of new cancer...
Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC
In a phase II study reported in the Journal of Clinical Oncology, Wu et al found that crizotinib (Xalkori) was highly active in East Asian patients with ROS1-positive advanced non–small cell lung cancer (NSCLC). Study Details In the study, 127 patients from 37 sites in China, Japan,...
Axicabtagene Ciloleucel CAR T-Cell Therapy Active in Refractory Large B-Cell Lymphoma
As reported at the 2017 American Society of Hematology (ASH) Meeting & Exposition and in The New England Journal of Medicine by Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center, and colleagues, a phase II trial has shown high activity of autologous anti-CD19 chimeric...
Updated NCCN Guidelines® for Newly Diagnosed Glioblastoma
THE NATIONAL COMPREHENSIVE Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Central Nervous System Cancers (NCCN Guidelines®) to recommend alternating electric field therapy (also known as tumor-treating fields, Optune) in combination with temozolomide as a...
A Clinician’s Guide to Treating Patients With Glioblastoma
Glioblastoma, a grade 4 astrocytoma, is the most common and most aggressive form of primary brain tumors in adults. The most recent guidance on molecular profiling, diagnostic and prognostic factors, and treatments for newly diagnosed and recurrent diseases was described in the Journal of Oncology ...
Modest Weight Loss Reduces Breast Cancer Risk
Evidence of the numerous health benefits of weight loss continues to mount, and the hope is that doctors and patients are listening. A large observational study presented at the 2017 San Antonio Breast Cancer Symposium showed that weight loss of more than 5% is associated with a significantly lower ...
AACR 2018: Prototype Assays Suggest Highly Specific Blood Test to Screen for Cancer Is Feasible
Initial findings from the Circulating Cell-Free Genome Atlas (CCGA) study showed that prototype sequencing assays tested in this analysis may facilitate the development of a highly specific blood test for early cancer detection, according to data presented at the American Association for Cancer...
Lower-Dose Radiation in HPV-Positive Head and Neck Cancers After Induction Chemotherapy
The results of a phase II clinical trial suggest that patients with head and neck cancers associated with the human papillomavirus (HPV) may receive significantly lower doses of radiation safely and effectively after response to induction chemotherapy.1 These findings from the OPTIMA study,...
Enormous Cost of Failure to Screen Heavy Smokers for Lung Nodules
In 2011 the American College of Radiology Imaging Network (ACRIN) group published its publicly funded study of three annual screening chest computed tomography (CT) scans among heavy smokers aged 55 to 74.1 The results remain the first and only screening study for any cancer demonstrating a...
AACR 2018: Crizotinib Yielded a High Objective Response Rate for Adult Patients With ALK-Positive Inflammatory Myofibroblastic Tumor
Among patients with inoperable, advanced, or metastatic ALK-positive inflammatory myofibroblastic tumor, 50% were confirmed to have partial or complete tumor shrinkage after treatment with the ALK-targeted anticancer therapeutic agent crizotinib (Xalkori), according to data from the phase II EORTC...
Racial/Ethnic Disparities in Liver Cancer Incidence in California
In a study among California residents reported in the Journal of the National Cancer Institute, Pham et al found that those designated as Asian/Pacific Islanders were at elevated risk of hepatocellular carcinoma (HCC) vs other racial/ethnic groups, with the highest risk observed among Southeast...
ELCC 2018: Second-Line Tyrosine Kinase Inhibitor Therapy Demonstrates Clinical Benefit in EGFR-Mutated NSCLC With Leptomeningeal Metastasis
Erlotinib (Tarceva) or high-dose erlotinib provides benefit in patients with epidermal growth factor receptor (EGFR) mutated non–small cell lung cancer (NSCLC) who develop leptomeningeal metastasis during or after treatment with a tyrosine kinase inhibitor. Findings supporting second-line...
Larotrectinib in Pediatric Solid Tumors With TRK Gene Fusions
As reported in The Lancet Oncology by Laetsch et al, phase I results from an ongoing phase I/II trial have shown activity of the TRK kinase inhibitor larotrectinib in pediatric patients with solid tumors harboring TRK fusions. Study Details In the study, 24 patients in a dose-escalation cohort...
Targeted Sequencing Detection of Molecular Minimal Residual Disease and Prognosis in AML
In a study reported in The New England Journal of Medicine, Jongen-Lavrencic et al found that molecular minimal residual disease identified by next-generation sequencing during complete remission was associated with increased risk of relapse and mortality over 4 years of follow-up in patients with...
mTOR Inhibitor Plus Endocrine Therapy in Postmenopausal Women With Advanced ER-Positive, HER2-Negative Breast Cancer
In the phase II BOLERO-4 trial reported in JAMA Oncology, Royce et al found that the combination of the mTOR inhibitor everolimus (Afinitor) and endocrine therapy was active in first-line treatment of postmenopausal women with advanced estrogen receptor (ER)-positive, human epidermal growth factor...
Emerging Thoughts About the Immune Landscape in Pancreatic Cancer
LONG-TERM SURVIVORS of pancreatic cancer display evidence of enhanced tumor-specific T-cell responses that are associated with unique neoepitope quality but not quantity, according to Steven D. Leach, MD, Director of the Norris Cotton Cancer Center and the Preston T. and Virginia R. Kelsey...
Four Years Posttreatment, Exercise Improves Physical Activity Levels, Reduces Fatigue in Patients With Breast and Colon Cancers
IN PATIENTS WITH breast and colon cancers, a physical exercise intervention conducted during adjuvant chemotherapy improved total physical activity levels 4 years after treatment, with a trend toward less fatigue, according to a follow-up study from the randomized multicenter PACT study, presented...
Greater Understanding of Family Dynamics May Help Cancer Teams Guide, Support Patients
WHETHER THEY are parents themselves or dealing with their own parents, patients with cancer often look to their health-care team to help guide these relationships, but data on how best to help are lacking, according to two poster presentations at the 2018 American Psychosocial Oncology Society...
Cardiovascular Risk Factors, Cardiac Events, and Survival in Patients With Breast Cancer Enrolled in SWOG Clinical Trials
In a study reported in the Journal of Clinical Oncology, Hershman et al found that each additional baseline cardiovascular disease risk factor was associated with increased risk for cardiac events and death among Medicare patients who had been enrolled in SWOG trials in breast cancer. Study...
Vinflunine May Benefit Selected Patients With Penile Cancer
PENILE CANCER is rare, outcomes remain poor, and there are few data from randomized trials to guide treatment decisions. However, in the small phase II VinCaP study, presented at the 2018 Genitourinary Cancers Symposium, 45.5% of patients with advanced or metastatic penile cancer had a clinical...
GU Symposium Focuses on Prognostic Model in Urothelial Cancer, Novel Therapies for Prostate and Kidney Cancers
THE 2018 GENITOURINARY Cancers Symposium hosted an international audience of oncologists and other stakeholders to hear about the latest advances in the field. We have included coverage of many of the top news stories from the meeting in previous issues of The ASCO Post. Here are summaries of a few ...
Intratumor Heterogeneity of Head and Neck Cancers May Have Therapeutic Implications
A RETROSPECTIVE STUDY of The Cancer Genome Atlas may have therapy-specific implications for patients with head and neck squamous cell carcinoma, according to data presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium.1 This first analysis of the relationship between intratumor...
Potent Anti-HER2 Agents on the Horizon
THANKS TO the efficacy of five approved anti-HER2 agents, patients with HER2-positive breast cancer have overall survival numbers that are as good as, or better than, their HER2-negative counterparts. With the next generation of anti-HER2 therapies in clinical trials, these outcomes may become even ...
Encorafenib Plus Binimetinib Improves Progression-Free Survival vs Vemurafenib in Advanced BRAF-Mutant Melanoma
IN THE PHASE III COLUMBUS trial reported in The Lancet Oncology, Reinhard Dummer, MD, of University Hospital Zurich, and colleagues found that the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib improved progression-free survival vs vemurafenib (Zelboraf) in...
Cardiovascular Toxicity and Carfilzomib Treatment in Multiple Myeloma
The proteasome inhibitor carfilzomib (Kyprolis) has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy may come with the risk of cardiovascular problems in a higher-than-expected...
BTK Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma
A phase II study (ACE-LY-004) reported in The Lancet by Michael Wang, MD, of The University of Texas MD Anderson Cancer Center, and colleagues showed durable responses with the Bruton tyrosine kinase inhibitor acalabrutinib (Calquence) in patients with relapsed or refractory mantle cell lymphoma....
The Clinical Significance of Clinicaltrials.gov
“I think I found the trial that is going to save your life,” Stefanie Joho’s sister said after checking out the ClinicalTrials.gov website. “And sure enough, it did. That is not an exaggeration. That is exactly what happened,” Ms. Joho, a health advocate and consultant based in Philadelphia, told...
